Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

被引:17
作者
Nakatani, Yukihiro [1 ,3 ]
Kato, Ken [1 ]
Shoji, Hirokazu [1 ]
Iwasa, Satoru [1 ]
Honma, Yoshitaka [1 ]
Takashima, Atsuo [1 ]
Ushijima, Toshikazu [2 ,3 ]
Ito, Yoshinori [4 ]
Itami, Jun [5 ]
Boku, Narikazu [1 ]
机构
[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan
[2] Natl Canc Ctr, Res Inst, Div Epigen, Tokyo, Japan
[3] Juntendo Univ, Grad Sch Med, Course Adv Clin Res Canc, Tokyo, Japan
[4] Showa Univ, Sch Med, Dept Radiol, Shinagawa Ku, Tokyo, Japan
[5] Natl Canc Ctr, Radiat Oncol Div, Tokyo, Japan
关键词
Chemoradiotherapy; Esophageal cancer; Involved field irradiation; Late toxicity; SQUAMOUS-CELL CARCINOMA; DEFINITIVE CHEMORADIOTHERAPY; RADIATION-THERAPY; PHASE-II; TRIAL;
D O I
10.1007/s10147-020-01652-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The optimal radiation field of chemoradiation therapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC) is unknown. This retrospective study compared efficacy and safety of two CRT modalities, involved field irradiation (IFI) and elective nodal irradiation (ENI), when treating patients with clinical stage I (T1bN0M0) ESCC. Methods Patients had received 60 Gy CRT concurrently with 5-FU and cisplatin between January 2000 and December 2012. The clinical target volume of IFI was limited to the primary tumor plus a 2-cm craniocaudal margin; that of ENI covered the primary tumor plus the field of regional lymph nodes. Results One hundred and ninety-five patients were selected (IFI group, 78; ENI group, 117). The 5-year overall, cause-specific and progression-free survival rates were 90.5%, 91.6% and 77.6% in the IFI group, and 72.5%, 88.3%, 57.9% in the ENI group, respectively. Of recurrent patients (n = 16 in the IF and n = 33 in the ENI groups) after achieving complete remission, 12 (75%) in the IFI group received definitive salvage therapy, 11 (33%) patients did in the ENI group. More patients died of diseases other than esophageal cancer in the ENI group (n = 29, 25%) than in the IFI group (n = 3, 3.8%). Multivariate analysis identified ENI (HR 3.63 [1.78-7.38], p < 0.001), age >= 70 (HR 2.65 [1.53-4.58], p < 0.001) and PS = 1 (HR 2.36 [1.33-4.18], p = 0.003) as poor prognostic factors for OS. Conclusions IF irradiation would be better than ENI for the patients with stage I ESCC who received definitive chemoradiotherapy.
引用
收藏
页码:1098 / 1104
页数:7
相关论文
共 50 条
  • [41] Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: A multicenter retrospective study (KROG 21-10)
    Song, Jun Yeong
    Moon, Sung Ho
    Suh, Yang-Gun
    Kim, Jong-Hoon
    Oh, Dongryul
    Noh, Jae Myoung
    Jeong, Jae-Uk
    Cho, Ick Joon
    Kang, Min Kyu
    Kim, Jin Hee
    Kimi, Young Suk
    Kimj, Hun Jung
    Park, Woo-Yoon
    Kim, Byoung Hyuck
    Kim, Hak Jae
    RADIOTHERAPY AND ONCOLOGY, 2023, 189
  • [42] Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis
    Liu, Tingting
    Ding, Silu
    Dang, Jun
    Wang, Hui
    Chen, Jun
    Li, Guang
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [43] Patterns of failure and long-term outcome of postoperative radiotherapy on the survival of patients with pathological T3N0M0 esophageal cancer
    Song, Chunyang
    Zhu, Shuchai
    Xu, Jinrui
    Su, Jingwei
    Zhang, Xueyuan
    Deng, Wenzhao
    Zhao, Xiaohan
    Shen, Wenbin
    FRONTIERS IN SURGERY, 2022, 9
  • [44] Intraoperative Radiotherapy in the Combination of Adjuvant Chemotherapy for the Treatment of pT3N0M0 Rectal Cancer After Radical Surgery
    Zhang, Qing
    Tey, Jeremy
    Yang, Zhe
    Li, Ping
    Peng, Lihua
    Jiang, Ruiyao
    Xiong, Fei
    Fu, Shen
    Lu, Jiade J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 8 - 12
  • [45] Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China
    Lyu, Jiahua
    Yisikandaer, Abulimiti
    Li, Tao
    Zhang, Xiaozhi
    Wang, Xiaohu
    Tian, Zhongge
    Chen, Long
    Lu, Bing
    Chen, Hong
    Yang, Jie
    Wang, Qifeng
    Zhang, Jinnrong
    Ma, Youguo
    Liu, Rui
    Liu, Ruifeng
    Hage, Aiguri
    Lang, Jinyi
    CANCER MEDICINE, 2020, 9 (20): : 7460 - 7468
  • [46] Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma
    Asbell, SO
    Martz, KL
    Shin, KH
    Sause, WT
    Doggett, RL
    Perez, CA
    Pilepich, MV
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04): : 769 - 782
  • [47] Impact of chemotherapy on prognosis of resectable pathological T3N0M0 esophageal cancer patients: a population-based study
    Gu, Xiang
    Ge, Yizhi
    Liu, Jia
    Ding, Qian
    Chu, Junfeng
    Tian, Guangyu
    Chen, Xiaojun
    FUTURE ONCOLOGY, 2021, 17 (30) : 3925 - 3940
  • [48] Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis
    Tingting Liu
    Silu Ding
    Jun Dang
    Hui Wang
    Jun Chen
    Guang Li
    Radiation Oncology, 14
  • [49] Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma
    Sun, Y.
    Duan, Q.
    Chen, X.
    Chen, W.
    Jin, X.
    Wu, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12) : 1498 - 1506
  • [50] Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation
    Li, Qiaofang
    Zhu, Shuchai
    Li, Shuguang
    Deng, Wenzhao
    MEDICINE, 2019, 98 (03)